https://www.selleckchem.com/products/AS703026.html
Prognostic factors were identified and research questions for future clinical trials were addressed. Prognostic factors were identified and research questions for future clinical trials were addressed. As next-generation sequencing (NGS) technology matures, various amplicon-based NGS tests for BRCA1/2 genotyping have been introduced. This study was designed to evaluate an NGS test using a newly released amplicon-based panel, AmpliSeq for Illumina BRCA Panel (AmpliSeq panel), for detection of clinically significant BRCA variants, and to
Like
Comment
Share
